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1. Introduction
Motivations
• Accounting for drug resistance in cancer requires considering the
level of cancer cell populations
• Phenotype heterogeneity in cancer cell populations is likely the
main cause of drug resistance
•Heterogeneity in cancer cell populations may be due to fast back-
ward evolution (atavistic theory)
•We can assess it by biological and mathematical models of evolv-
ing heterogeneous cell populations
• Therapeutic strategies should rely on optimal control algorithms in
such models of heterogeneity
Executive summary
BACKGROUND Drug-induced drug resistance in cancer has
been attributed to diverse biological mechanisms at the individual
cell or cell population scale, relying on stochastically or epigenet-
ically varying expression of phenotypes at the single cell level,
and on the adaptability of tumours at the cell population level.
SCOPE OF THIS REVIEW We focus on intra-tumour hetero-
geneity, namely between-cell variability within cancer cell popu-
lations, to account for drug resistance. To shed light on such het-
erogeneity, we review evolutionary mechanisms that encompass
the great evolution that has designed multicellular organisms, as
well as smaller windows of evolution on the time scale of human
disease. We also present mathematical models used to predict
drug resistance in cancer and optimal control methods that can
circumvent it in combined therapeutic strategies.
MAJOR CONCLUSIONS Plasticity in cancer cells, i.e., par-
tial reversal to a stem-like status in individual cells and resulting
adaptability of cancer cell populations, may be viewed as back-
ward evolution making cancer cell populations resistant to drug
insult. This reversible plasticity is captured by mathematical mod-
els that incorporate between-cell heterogeneity through continu-
ous phenotypic variables. Such models have the benefit of being
compatible with optimal control methods for the design of opti-
mised therapeutic protocols involving combinations of cytotoxic
and cytostatic treatments with epigenetic drugs and immunother-
apies.
GENERAL SIGNIFICANCE Gathering knowledge from cancer
and evolutionary biology with physiologically based mathemati-
cal models of cell population dynamics should provide oncolo-
gists with a rationale to design optimised therapeutic strategies
to circumvent drug resistance, that still remains a major pitfall of
cancer therapeutics.
2. An evolutionary perspective
“Nothing in biology makes sense except in the light of evolution”
(Theodosius Dobzhansky)
... But what evolution? Have a look at the evolution of life on Earth:
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Figure 1: Tentative reconstruction of the evolution of life on Earth (Ref. [1]).
• The genes that have appeared in the process of development to
multicellularity are precisely those that are altered in cancer.
• In what order in evolution, from 1) proliferation+apoptosis to 2) cell
differentiation+division of work, and to 3) epigenetic control of dif-
ferentiation and proliferation?
•Reconstituting the phylogeny of this ‘multicellularity toolkit’ should
shed light on the robustness or fragility of genes that have been
altered in cancer.
• Attacking cancer on proliferation is precisely attacking its robust-
ness. It would be better to attack its weaknesses (e.g. absence of
adaptive immune response).
Heterogeneity in cancer cell populations
•Conditions of oxygenation and of intercellular communications are
quite poor in cancer cell populations, sending back tumours to
very primitive forms of multicellularity (e.g., stochastic distribution
of cellular functions without coordination)
• These two necessary conditions of multicellularity are closely re-
lated to one another, since intercellular communications, that rely
in particular on gap junctions (appeared during the long oxygena-
tion epoch of developing multicellular life and often altered in can-
cer), consume high quantities of energy
•High energy resources physiologically rely on the oxygen-
dependent tricarboxylic acid (TCA, aka Krebs) cycle in mitochon-
dria, power plants of the cell, that are altered in cancer: the War-
burg effect describes the fact that cancer cells are hardly able to
make their mitochondria work properly and depend on the poor
energy-producing process of anaerobic glycolysis
The atavistic theory of cancer
•Why drug resistance in cancer, not in healthy, cell populations?
We can find some answers in the atavistic theory of cancer (Davies
and Lineweaver 2011).
• According to the atavistic theory, cancer is a ‘backward evolution’
from a sophisticated form of multicellularity (us), in which epige-
netic processes control gene regulatory networks of transcription
factors: differentiation factors, p53, etc., that physiologically con-
trol the basis of cellular life, i.e., proliferation.
•We bear in our genomes many attempts of species evolution since
billions of years; dead-end tracks (‘unused attractors’ in S. Huang
and S. Kauffman’s version of the Waddington landscape) have
been silenced (e.g., by epigenetic enzymes, resulting in evolution-
ary barriers in this landscape), but are still there.
• In cancer, global regulations are lost, differentiation is out of con-
trol, so that local proliferations without regulation overcome; so-
phisticated adaptive epigenetic mechanisms are present, not con-
trolling proliferation, but serving it.
•Conditions of oxygenation and of intercellular communications
are quite poor in cancer cell populations, sending back tumours
to locally organised, very primitive forms of multicellularity (e.g.,
stochastic distribution of cellular functions without coordination),
escaping external control.
• The basic cancer cell is also highly plastic and highly capable of
adaptation to a hostile environment, as were its ancestors in a
remote past of our planet (poor O2, acidic environment, high UV
radiations,...) and likely presently even more.
The Waddington landscape revisited
The classical ‘metaphoric’ Waddington landscape (1957)
Figure 2: Epigenetic cell differentiation in a given genome.
Epigenetic drugs to target bifurcations in a plastic landscape?
Figure 3: A Waddington landscape revisited (Sui Huang, 2013).
“Nothing in evolution makes sense except in the light of systems
biology” (S. Huang, 2012)
3. Assessing drug resistance
Adaptive dynamics called to predict evolution of cell populations in
the presence of drug pressure:
∂
∂t
nH(x, t) =
[
rH(x)
1 + kHu2(t)
− dH(x)IH(t)− u1(t)µH(x)
]
nH(x, t)
∂
∂t
nC(x, t) =
[
rC(x)
1 + kCu2(t)
− dC(x)IC(t)− u1(t)µC(x)
]
nC(x, t)
Environment variables (logistic terms):
IH(t) = aHH .ρH(t) + aHC.ρC(t), IC(t) = aCH .ρH(t) + aCC.ρC(t),
with ρH(t) =
∫ 1
0 nH(x, t) dx, ρC(t) =
∫ 1
0 nC(x, t) dx,
u1 cytotoxic, u2 cytostatic drugs.
Figure 4: Healthy cells: preserved (Ref. [2]).
Figure 5: Cancer cells: eventually extinct (Ref. [2]).
4. Perspectives in therapeutics
• Systematically relating the phylogeny of multicellularity to the phy-
logeny of cancers (an evo-devo-cancer viewpoint, cf. Ref. [1])
should shed light on the responsible genes of cancer emergence
and progression as possible druggable targets.
•Models of adaptive dynamics models for cell populations are rel-
evant to represent their evolution under drug pressure, cf. Ref. [2].
• Taking limitations in space and diffusion of drugs and nutrients is
an option when some geometry of the tumour population is known,
cf. Ref. [3].
• Epigenetic control genes might offer such targets to stop the emer-
gence of drug resistance (blocking the rise of DTPs, cf. Ref. [4]).
•Optimal control algorithms for anticancer drug infusion are being
designed as proof of concept, aiming to block the emergence of
drug resistance, cf. Ref. [5]. These should be developed in close
collaboration with oncologists in the clinic in the forthcoming years.
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